Unipharma Co., Ltd.

As of June 30, 2026, Unipharma Co., Ltd. carries a market capitalization of 401.16M, placing it among publicly traded companies globally. Its enterprise value stands at 305.90M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Unipharma Co., Ltd. has 35.50M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Unipharma Co., Ltd. maintains a current ratio of 4.85, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Unipharma Co., Ltd.'s stock has declined approximately 5.71% over the past 52 weeks. The 50-day moving average sits at 11.68, while the 200-day moving average is 12.12.

As of June 30, 2026, Unipharma Co., Ltd. holds 107.59M in cash and equivalents against 12.33M in total debt, resulting in a net debt position of -20.08M. Total book value stands at 196.80M, with working capital of 123.18M providing operational flexibility.